Voyager initiated RESTORE-1, a Phase 2, randomized, placebo-surgery controlled, double-blinded, multi-center clinical trial to evaluate the safety and efficacy of VY-AADC for the potential treatment of advancing Parkinson’s disease. Multiple clinical trial sites have been selected for participation in the RESTORE-1 trial.
RESTORE-1 is a clinical trial for people with advancing Parkinson’s disease. If your response to Parkinson’s disease medications has become unpredictable or isn’t what it used to be, this clinical trial may be an option that you should discuss with your doctor.
For more information about the RESTORE-1 clinical trial, including an eligibility questionnaire, please visit restore1study.com.